Mark Beards is an accomplished executive with extensive experience in the biopharmaceutical and biotechnology sectors. Currently serving as Interim CEO at Calon Cardio, Mark leads the development of advanced left ventricular assist devices (LVADs). In addition, Mark holds chairman positions at PFU Therapeutics and AMPLY Discovery, focusing on innovative medical technologies. As the owner of Fountainhead Consulting Limited, Mark provides strategic guidance to global pharmaceutical and biotechnology companies. Mark also contributes as an expert at GLG, a strategic advisor at Mendel Partners, and previously held leadership roles at Sutura Therapeutics, UTILITY therapeutics, and Celixir. Mark's educational background includes advanced degrees in Mathematics from the University of Oxford and professional qualifications in accounting.
This person is not in the org chart
This person is not in any teams
This person is not in any offices